Clinical Research
TRIUMPH-4 Retatrutide Trial Design 2026 | Artemis Labs
TRIUMPH-4 Trial Design & What We Know About Retatrutide (2026)
Status note (May 2026): The TRIUMPH-4 Phase 3 retatrutide trial is ongoing. As of this update only the protocol/design paper has been published (DOM, Jan 2026, PMID 41090431). The peer-reviewed efficacy data referenced throughout this post is the published Phase 2 Jastreboff et al. NEJM 2023 trial (PMID 37366315), which reported up to 24.2% mean body-weight reduction at 48 weeks at the 12 mg dose. Any “TRIUMPH-4 Phase 3 outcome” figure circulating in third-party blog content is currently UNVERIFIED — Phase 3 readout pending.
Research Highlights
- Published Phase 2 data (Jastreboff 2023, PMID 37366315): Up to ~24.2% mean body-weight reduction at 48 weeks at the highest tolerated dose (12 mg weekly); ~338 participants; double-blind RCT.
- TRIUMPH-4 Phase 3 status: Trial in progress. Protocol/design paper published (DOM Jan 2026, PMID 41090431); efficacy readout pending. No peer-reviewed Phase 3 weight-loss percentage is publishable yet.
- Mechanism (validated by Phase 2 work): Retatrutide co-activates GLP-1, GIP, and glucagon receptors. The triple-receptor design produced the largest effect size in the GLP-1-family Phase 2 literature.
Why TRIUMPH-4 Matters
TRIUMPH-4 is the Phase 3 program designed to confirm and extend the Phase 2 efficacy of retatrutide — the first triple-receptor (GLP-1 / GIP / glucagon) agonist to advance into late-stage clinical research. The Phase 2 data published by Jastreboff et al. in NEJM (2023) established a striking effect-size signal: up to ~24.2% mean body-weight reduction at 48 weeks at the 12 mg weekly dose, with a clear concentration-response curve and a manageable safety profile dominated by GI adverse events.
Phase 3 confirmation matters because Phase 2 trials enroll smaller populations under tightly controlled conditions. Phase 3 tests whether the same mechanism produces durable, reproducible, and safe effects in larger and more diverse research populations — and it is the regulatory threshold for eventual therapeutic indications.
What Phase 2 Actually Showed (Jastreboff et al., NEJM 2023)
The Phase 2 trial is the basis for everything currently known about retatrutide efficacy. Key features:
| Aspect | Detail |
|---|---|
| Phase | 2 |
| Trial reference | Jastreboff AM et al., NEJM 2023 (PMID 37366315) |
| Sample size | ~338 participants |
| Population | Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity |
| Dosing | 1, 4, 8, or 12 mg weekly (retatrutide) vs. placebo |
| Duration | 48 weeks |
| Primary endpoint | Percent change in body weight from baseline |
| Headline efficacy | Up to ~24.2% mean reduction at 48 weeks (12 mg) |
| Safety profile | GI adverse events dominated; serious AEs uncommon |
The Phase 2 trial’s central finding was a clear dose-response gradient and a triple-mechanism effect size that exceeded published dual-agonist (tirzepatide) baselines in non-head-to-head comparison.
TRIUMPH-4 Phase 3: What We Know From the Protocol
The TRIUMPH-4 protocol paper (DOM, Jan 2026, PMID 41090431) describes the Phase 3 design:
- Status: Ongoing — efficacy results not yet published
- Design: Multi-arm, double-blind, randomized controlled Phase 3 trial of retatrutide vs. placebo (and active comparators in companion TRIUMPH-family trials) in adults with obesity
- Primary endpoint: Change in body weight from baseline at the trial endpoint
- Population: Adults with obesity / overweight + comorbidities (refer to ClinicalTrials.gov for current enrollment criteria)
Until the Phase 3 efficacy readout is peer-reviewed, no specific TRIUMPH-4 weight-loss percentage should be cited. The figures circulating in third-party content (including in some research-peptide vendor blogs through Q1 2026) appear to have been fabricated and should be treated as unverified.
What Phase 2 Implied About the Mechanism
The Phase 2 trial is informative for mechanism research even though we await Phase 3 confirmation. Three points emerge:
- Triple agonism produced a steep concentration-response curve. Effect size scaled monotonically with retatrutide concentration up to the 12 mg dose, suggesting genuine triple-receptor synergy rather than receptor saturation.
- GI tolerability was the dominant safety signal. GI adverse events were frequent at higher doses, consistent with the glucagon-receptor contribution to GI motility. Discontinuation rates were elevated relative to dual-agonist references.
- Body composition trended toward favorable adipose-vs-lean ratio. Phase 2 imaging substudies supported the interpretation that the weight loss was predominantly fat mass.
These signals frame the questions Phase 3 will answer: do they replicate in a larger population over a longer duration with better-characterized safety endpoints?
TRIUMPH-4 vs. SURMOUNT-1: What the Comparison Currently Supports
Direct apples-to-apples comparison of TRIUMPH-4 vs. SURMOUNT-1 is not yet possible because TRIUMPH-4 Phase 3 outcomes are unpublished. The currently defensible comparison is Phase 2 retatrutide vs. Phase 3 tirzepatide (SURMOUNT-1):
| Metric | Retatrutide Phase 2 (Jastreboff 2023, 12 mg) | Tirzepatide SURMOUNT-1 (15 mg) |
|---|---|---|
| Mean Weight Loss | ~24.2% at 48 weeks | ~20.9% at 72 weeks |
| Trial Phase | 2 | 3 |
| Sample Size | ~338 | ~2,539 |
| Endpoint Duration | 48 weeks | 72 weeks |
| GI Burden | Higher than dual-agonist baseline | ~37% nausea incidence |
| Mechanism | GLP-1 + GIP + glucagon | GLP-1 + GIP |
The Phase 2 retatrutide data is encouraging but cross-phase comparisons are limited. The TRIUMPH-4 Phase 3 readout, when published, will provide the appropriate same-phase comparator.
Why “Triple Agonism” is Mechanistically Different
Phase 2 evidence supports — but does not yet definitively confirm — that triple-receptor agonism is mechanistically distinct from dual-agonism, not just incrementally additive:
- GLP-1 receptor: Appetite suppression via hypothalamic signaling, glucose-dependent insulin release, delayed gastric emptying.
- GIP receptor: Insulin amplification, modulation of postprandial lipid dynamics, possible visceral-fat-specific effects.
- Glucagon receptor: Hepatic glucose mobilization, lipolytic / β-oxidation upregulation, thermogenic energy expenditure.
The glucagon arm contributes increased energy expenditure on top of GLP-1’s appetite suppression — a mechanism the dual-agonist (tirzepatide) does not engage. This is the theoretical basis for the larger effect size and explains why GI burden is higher (glucagon-receptor activation has known GI motility effects).
What This Means for Researchers Today
For researchers planning retatrutide protocol work in 2026:
- Cite Phase 2 for currently-defensible retatrutide outcomes (Jastreboff 2023, PMID 37366315).
- Cite the Phase 3 protocol (DOM 2026, PMID 41090431) for trial design — do not cite Phase 3 efficacy yet.
- Watch for the Phase 3 readout through ClinicalTrials.gov and NEJM / Lancet.
- Verify your retatrutide supply with third-party HPLC + MS. Independent re-testing surveys documented ~47% failure rates in the 2025–2026 research-market retatrutide supply. See our retatrutide quality crisis report.
- Design Phase 2-anchored protocols — they reflect verified evidence rather than speculative Phase 3 figures.
Common Questions
Q: What is the published TRIUMPH-4 efficacy result?
There is no published TRIUMPH-4 Phase 3 efficacy result as of May 2026. Only the protocol paper (DOM Jan 2026, PMID 41090431) is published. The relevant peer-reviewed retatrutide efficacy data is the Phase 2 Jastreboff et al. NEJM 2023 paper (PMID 37366315), which documented up to ~24.2% mean weight reduction at 48 weeks at the 12 mg dose.
Q: What about the 23.7% or 28.7% figures circulating online?
Those figures appear in third-party content (including some research-peptide vendor blogs in Q1 2026) but are unverified against any published Phase 3 publication. Treat them as fabricated until a peer-reviewed Phase 3 readout publishes.
Q: When will Phase 3 results publish?
Watch ClinicalTrials.gov, NEJM, and Lancet. Phase 3 weight-loss trial readouts typically publish 6–18 months after primary endpoint completion. Until then, cite Phase 2.
Q: Is retatrutide still worth researching ahead of Phase 3?
Yes — the Phase 2 effect size and mechanism rationale support continued research. Mechanism studies, comparative pharmacology, in vitro receptor work, and in vivo animal model research can all proceed using Phase 2-anchored protocol designs.
Q: How does the retatrutide quality crisis interact with this?
The clinical trials (Phase 2 + ongoing Phase 3) use pharmaceutical-grade retatrutide synthesized under cGMP. Research-market retatrutide showed ~47% failure rates in independent testing during 2025–2026. Replication studies must verify supplier-supplied retatrutide via third-party HPLC + MS. See our retatrutide quality crisis report.
Q: What is the safety signal we should pay attention to?
GI tolerability dominates the Phase 2 safety profile, with higher rates than dual-agonist comparators. Pancreatitis, gallstone, and cardiovascular signals from Phase 2 were not statistically meaningful but warrant continued monitoring in Phase 3 and post-marketing settings.
Related Products
- Retatrutide — independently re-tested triple-agonist research compound
- Tirzepatide — dual-agonist comparator
- Cagrilintide — amylin-pathway research compound
Related Research
- Complete Guide to Weight Loss Research Peptides 2026 — pillar
- Tirzepatide vs Retatrutide Comparison
- Retatrutide Quality Crisis Report
- SURMOUNT-1 Tirzepatide Trial Deep Dive
- GLP-1 Receptor Agonism Explained
- Retatrutide Verification Checklist
Verified References
Canonical, WebFetch-verified PMIDs / DOIs are consolidated in
Product Catalog/MASTER_RESEARCH_CITATIONS.md. Two anchor references for this post:
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. NEJM 2023. PMID: 37366315. (Verified — see MASTER_RESEARCH_CITATIONS.md.)
- TRIUMPH-4 protocol paper. Diabetes Obesity & Metabolism, January 2026. PMID: 41090431. Phase 3 trial design; efficacy results pending.
Any other PMID or DOI in this category must be WebFetch-verified before citation.
Last updated: May 20, 2026 (rewritten to remove unverified Phase 3 efficacy figures). For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.
